Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome

Open access
Melander, Catherine, Salle[Combining Acute Accent]e, Marion, Trolliet, Pierre, Candon, Sophie, Belenfant, Xavier, Daugas, Eric, Re[Combining Acute Accent]my, Phillipe, Zarrouk, Virginie, Pillebout, Evange[Combining Acute Accent]line, Jacquot, Christian, Boffa, Jean-Jacques, Karras, Alexandre, Masse, Virginie, Lesavre, Philippe, Elie, Caroline, Brocheriou, Isabelle, Knebelmann, Bertrand, Noe[Combining Diaeresis]l, Laure-He[Combining Acute Accent]le[Combining Grave Accent]ne, Fakhouri, Fadi·2009·Clinical Journal of the American Society of Nephrology

Abstract

BACKGROUND AND OBJECTIVES: Standard treatment for lupus nephritis, including corticosteroids and cyclophosphamide, is efficient but is still associated with refractory or relapsing disease, or severe deleterious effects. Rituximab, a monoclonal chimeric anti-B cell antibody, is increasingly used in patients with lupus nephritis, but reported series were small and had a short follow-up. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The authors analyzed clinical and histologic data of 20 patients who were treated with rituximab for lupus nephritis and followed up for at least 12 mo. RESULTS: Nineteen women and one man received rituximab as induction treatment for an active class IV (15 cases) or class V (5 cases) lupus nephritis. Rituximab was given for lupus nephritis refractory to standard treatment (12 cases), for relapsing disease (6 cases), or as first-line treatment (2 cases). Three patients received cyclophosphamide concomitantly with rituximab. Ten received new injections of rituximab as maintenance therapy. Side effects included mainly five infections and four moderate neutropenias. After a median follow-up of 22 mo, complete or partial renal remission was obtained in 12 patients (60%). Lupus nephritis relapsed in one patient, who responded to a new course of rituximab. The achievement of B cell depletion 1 mo after rituximab, which negatively correlated with black ethnicity and hypoalbuminemia, was strongly associated with renal response. Rapidly progressive glomerulonephritis did not respond to rituximab. CONCLUSION: Rituximab is an interesting therapeutic option in relapsing or refractory lupus nephritis when early B cell depletion is obtained.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.04030808

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 169

Metadata

Authors
Melander, C., Salle[Combining Acute Accent]e, M., Trolliet, P., Candon, S., Belenfant, X., Daugas, E., Re[Combining Acute Accent]my, P., Zarrouk, V., Pillebout, E. A. A., Jacquot, C., Boffa, J.-J., Karras, A., Masse, V., Lesavre, P., Elie, C., Brocheriou, I., Knebelmann, B., Noe[Combining Diaeresis]l, L.-H. A. A. G. A., & Fakhouri, F.
Venue
Clinical Journal of the American Society of Nephrology
Published
2009-03
Volume
4
Issue
3
Pages
579-587
ISSN
1555-9041 (ISSN-L)
OpenAlex
W2133736867
Cited by
169
References
2
FWCI
12.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome. https://app.cochat.ai/papers/10.2215/cjn.04030808
The paper
Melander, C., Salle[Combining Acute Accent]e, M., Trolliet, P., Candon, S., Belenfant, X., Daugas, E., Re[Combining Acute Accent]my, P., Zarrouk, V., Pillebout, E. A. A., Jacquot, C., Boffa, J.-J., Karras, A., Masse, V., Lesavre, P., Elie, C., Brocheriou, I., Knebelmann, B., Noe[Combining Diaeresis]l, L.-H. A. A. G. A., & Fakhouri, F. (2009). Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.04030808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.